Thousands of NHS patients to access trials of personalised cancer ‘vaccines’
In a statement from the British National Health Service, the state-run healthcare system confirmed that thousands of cancer patients would be given “fast-tracked access to trials of personalised cancer vaccines.”
The statement read:
The NHS today announced it has treated its first patient in England with a personalised vaccine against their bowel cancer, in a clinical trial part of NHS England’s new Cancer Vaccine Launch Pad.
In a national first, father-of-four Elliot Phebve received the developmental jab at University Hospitals Birmingham NHS Foundation Trust, one of several sites taking part in the colorectal cancer vaccine trial sponsored by BioNTech SE.
The investigational cancer vaccines evaluated in the colorectal cancer trial are based on mRNA – the same technology used for the Pfizer-BioNTech COVID-19 vaccine – and are created by analysing a patient’s tumour to identify mutations specific to their own cancer. Using this information, medics then create an experimental individualised cancer vaccine.
https://www.england.nhs.uk/2024/05/thousands-of-nhs-patients-to-access-trials-of-personalised-cancer-vaccines/